TXN's inventory bet shows early returns, but recovery durability remains unproven

What happened

Texas Instruments' decision to maintain production during the downturn is paying off as demand rebounds, particularly in industrial and data-center segments. The Q1'26 revenue beat and strong guidance for Q2'26 suggest the strategy is gaining traction. However, the DeepValue master report warns that this may be a restock burst rather than a durable recovery, given management's own reference to a prior-year 'head fake'. Inventory days at 209 remain elevated, and the stock's high multiple (P/E 45.6) leaves little room for error. Trade risks tied to China (50% of revenue shipped into the region) add further downside if orders stall.

Implication

The next 6-9 months are critical: if revenue remains above $5.0B and inventory days fall below 200, the bullish thesis gains credibility. However, the risk of a 'false start' and tariff disruptions suggests a disciplined entry only if these checkpoints are met. The Silicon Labs acquisition adds execution risk in 2027. Investors should monitor Q2'26 earnings and management commentary for signs of broad-based demand, especially in industrial. Until then, the risk/reward is unattractive given the premium valuation.

Thesis delta

The article reinforces the near-term positive momentum from TXN's inventory strategy, aligning with the base-case scenario of a modest recovery. However, the master report's cautious stance on sustainability and margin protection tempers the bullish narrative. The core thesis shifts from 'betting on a recovery' to 'waiting for confirmation that this cycle is not a head fake, with industrial re-orders and inventory tightening as key proof points.' A failure to meet Q2'26 guidance would invalidate the recovery thesis entirely.